279,954 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Purchased by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. purchased a new position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 279,954 shares of the company's stock, valued at approximately $2,282,000. Jacobs Levy Equity Management Inc. owned 0.50% of Ginkgo Bioworks at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DNA. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Ginkgo Bioworks by 644.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company's stock worth $263,000 after purchasing an additional 27,978 shares during the period. Verition Fund Management LLC purchased a new position in Ginkgo Bioworks in the 3rd quarter valued at about $792,000. Algert Global LLC acquired a new stake in shares of Ginkgo Bioworks in the second quarter worth approximately $36,000. Wellington Wealth Strategies LLC. acquired a new stake in Ginkgo Bioworks during the 2nd quarter worth $41,000. Finally, Forbes J M & Co. LLP purchased a new stake in Ginkgo Bioworks during the 3rd quarter valued at about $1,019,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on DNA. TD Cowen upped their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a "buy" rating in a report on Friday, September 20th. BTIG Research boosted their price objective on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a report on Friday, August 23rd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $4.58.

Ginkgo Bioworks Trading Up 20.6 %

NYSE DNA traded up $1.99 on Friday, hitting $11.66. 2,864,527 shares of the stock were exchanged, compared to its average volume of 1,328,823. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $75.20. The firm has a 50-day simple moving average of $8.16. The firm has a market cap of $670.22 million, a P/E ratio of -0.89 and a beta of 1.17.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.